195 related articles for article (PubMed ID: 32413791)
1. Generation of a human induced pluripotent stem cell line derived from a Parkinson's disease patient carrying SNCA duplication.
Suzuki H; Egawa N; Kondo T; Imamura K; Enami T; Tsukita K; Suga M; Shibukawa R; Okanishi Y; Uchiyama T; Inoue H; Takahashi R
Stem Cell Res; 2020 May; 45():101828. PubMed ID: 32413791
[TBL] [Abstract][Full Text] [Related]
2. Generation of TWO G51D SNCA missense mutation iPSC lines (CRICKi011-A, CRICKi012-A) from two individuals at risk of Parkinson's disease.
Devito LG; Zanjani ZS; Evans JR; Scardamaglia A; Houlden H; Gandhi S; Healy L
Stem Cell Res; 2023 Sep; 71():103134. PubMed ID: 37336145
[TBL] [Abstract][Full Text] [Related]
3. Modeling Parkinson's disease using induced pluripotent stem cells.
Byers B; Lee HL; Reijo Pera R
Curr Neurol Neurosci Rep; 2012 Jun; 12(3):237-42. PubMed ID: 22538490
[TBL] [Abstract][Full Text] [Related]
4. Alpha-synuclein dynamics in induced pluripotent stem cell-derived dopaminergic neurons from a Parkinson's disease patient (PARK4) with SNCA triplication.
Fukusumi H; Togo K; Sumida M; Nakamori M; Obika S; Baba K; Shofuda T; Ito D; Okano H; Mochizuki H; Kanemura Y
FEBS Open Bio; 2021 Feb; 11(2):354-366. PubMed ID: 33301617
[TBL] [Abstract][Full Text] [Related]
5. Generation of an induced pluripotent stem cell line (EURACi014-A) from a Parkinson's disease patient with an A53T mutation in the SNCA gene by an integration-free reprogramming method.
Gilmozzi V; Gentile G; Riekschnitz DA; Volpato CB; Di Segni M; Silipigni R; Pramstaller PP; Hicks AA; Pichler I; Zanon A
Stem Cell Res; 2022 Apr; 60():102713. PubMed ID: 35189566
[TBL] [Abstract][Full Text] [Related]
6. Generation of gene-corrected iPSC line from Parkinson's disease patient iPSC line with alpha-SNCA A53T mutation.
Lee SY; Jeong S; Kim J; Chung SK
Stem Cell Res; 2018 Jul; 30():145-149. PubMed ID: 29906669
[TBL] [Abstract][Full Text] [Related]
7. Derivation, Characterization, and Neural Differentiation of Integration-Free Induced Pluripotent Stem Cell Lines from Parkinson's Disease Patients Carrying SNCA, LRRK2, PARK2, and GBA Mutations.
Momcilovic O; Sivapatham R; Oron TR; Meyer M; Mooney S; Rao MS; Zeng X
PLoS One; 2016; 11(5):e0154890. PubMed ID: 27191603
[TBL] [Abstract][Full Text] [Related]
8. Using High-Content Screening to Generate Single-Cell Gene-Corrected Patient-Derived iPS Clones Reveals Excess Alpha-Synuclein with Familial Parkinson's Disease Point Mutation A30P.
Barbuti P; Antony P; Santos B; Massart F; Cruciani G; Dording C; Arias J; Schwamborn J; Krüger R
Cells; 2020 Sep; 9(9):. PubMed ID: 32927687
[TBL] [Abstract][Full Text] [Related]
9. Demonstration of brain region-specific neuronal vulnerability in human iPSC-based model of familial Parkinson's disease.
Brazdis RM; Alecu JE; Marsch D; Dahms A; Simmnacher K; Lörentz S; Brendler A; Schneider Y; Marxreiter F; Roybon L; Winner B; Xiang W; Prots I
Hum Mol Genet; 2020 May; 29(7):1180-1191. PubMed ID: 32160287
[TBL] [Abstract][Full Text] [Related]
10. Modeling Parkinson's disease with induced pluripotent stem cells harboring α-synuclein mutations.
Singh Dolt K; Hammachi F; Kunath T
Brain Pathol; 2017 Jul; 27(4):545-551. PubMed ID: 28585381
[TBL] [Abstract][Full Text] [Related]
11. Cellular α-synuclein pathology is associated with bioenergetic dysfunction in Parkinson's iPSC-derived dopamine neurons.
Zambon F; Cherubini M; Fernandes HJR; Lang C; Ryan BJ; Volpato V; Bengoa-Vergniory N; Vingill S; Attar M; Booth HDE; Haenseler W; Vowles J; Bowden R; Webber C; Cowley SA; Wade-Martins R
Hum Mol Genet; 2019 Jun; 28(12):2001-2013. PubMed ID: 30753527
[TBL] [Abstract][Full Text] [Related]
12. Generation of three clones (JUCGRMi002-A, B, C) of induced pluripotent stem cells from a Parkinson's disease patient with SNCA duplication.
Ishikawa KI; Shiga T; Yoshino H; Nishioka K; Hattori N; Akamatsu W
Stem Cell Res; 2024 Feb; 74():103296. PubMed ID: 38154385
[TBL] [Abstract][Full Text] [Related]
13. Generation of an induced pluripotent stem cell line (CSC-32) from a patient with Parkinson's disease carrying a heterozygous variation p.A53T in the SNCA gene.
Azevedo C; Chumarina M; Serafimova E; Goldwurm S; Collin A; Roybon L; Savchenko E; Pomeshchik Y
Stem Cell Res; 2020 Mar; 43():101694. PubMed ID: 31954327
[TBL] [Abstract][Full Text] [Related]
14. SNCA triplication Parkinson's patient's iPSC-derived DA neurons accumulate α-synuclein and are susceptible to oxidative stress.
Byers B; Cord B; Nguyen HN; Schüle B; Fenno L; Lee PC; Deisseroth K; Langston JW; Pera RR; Palmer TD
PLoS One; 2011; 6(11):e26159. PubMed ID: 22110584
[TBL] [Abstract][Full Text] [Related]
15. Higher vulnerability and stress sensitivity of neuronal precursor cells carrying an alpha-synuclein gene triplication.
Flierl A; Oliveira LM; Falomir-Lockhart LJ; Mak SK; Hesley J; Soldner F; Arndt-Jovin DJ; Jaenisch R; Langston JW; Jovin TM; Schüle B
PLoS One; 2014; 9(11):e112413. PubMed ID: 25390032
[TBL] [Abstract][Full Text] [Related]
16. Generation of two iPS cell lines (HIHDNDi001-A and HIHDNDi001-B) from a Parkinson's disease patient carrying the heterozygous p.A30P mutation in SNCA.
Barbuti PA; Santos BFR; Dording CM; Cruciani G; Massart F; Hummel A; Krüger R
Stem Cell Res; 2020 Oct; 48():101951. PubMed ID: 32798915
[TBL] [Abstract][Full Text] [Related]
17. Modeling native and seeded Synuclein aggregation and related cellular dysfunctions in dopaminergic neurons derived by a new set of isogenic iPSC lines with SNCA multiplications.
Iannielli A; Luoni M; Giannelli SG; Ferese R; Ordazzo G; Fossati M; Raimondi A; Opazo F; Corti O; Prehn JHM; Gambardella S; Melki R; Broccoli V
Cell Death Dis; 2022 Oct; 13(10):881. PubMed ID: 36261424
[TBL] [Abstract][Full Text] [Related]
18. Parkinson's disease induced pluripotent stem cells with triplication of the α-synuclein locus.
Devine MJ; Ryten M; Vodicka P; Thomson AJ; Burdon T; Houlden H; Cavaleri F; Nagano M; Drummond NJ; Taanman JW; Schapira AH; Gwinn K; Hardy J; Lewis PA; Kunath T
Nat Commun; 2011 Aug; 2():440. PubMed ID: 21863007
[TBL] [Abstract][Full Text] [Related]
19. Targeted attenuation of elevated histone marks at SNCA alleviates α-synuclein in Parkinson's disease.
Guhathakurta S; Kim J; Adams L; Basu S; Song MK; Adler E; Je G; Fiadeiro MB; Kim YS
EMBO Mol Med; 2021 Feb; 13(2):e12188. PubMed ID: 33428332
[TBL] [Abstract][Full Text] [Related]
20. CRISPR-Cas9-Edited SNCA Knockout Human Induced Pluripotent Stem Cell-Derived Dopaminergic Neurons and Their Vulnerability to Neurotoxicity.
Inoue S; Nishimura K; Gima S; Nakano M; Takata K
Biol Pharm Bull; 2023; 46(3):517-522. PubMed ID: 36858582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
